CDNA · NASDAQ
CareDx, Inc
$69.41 +0.20 (+0.29%)
Company overview
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Exchange
- NASDAQ
- Market cap
- $3.6B
- Employees
- 644
- Headquarters
- South San Francisco, CA
- Website
- caredx.com
- CEO
- John Walter Hanna Jr.
- Listed
- July 17, 2014
- P/E
- -438.96
- Dividend yield
- 0.00%
Company financials
- Revenue
- $413M
- Gross profit
- $283M
- Operating income
- -$13.2M
- EBITDA
- $10.1M
- Net income
- -$8.2M
- EPS
- -$0.16
- Total assets
- $411M
- Total debt
- $17.8M
- Gross margin
- 68.56%
- Net margin
- -1.98%
- Earnings yield
- -0.23%
Showing FY 2025
CDNA
1D
NASDAQ
O68.54H70.48L67.43C69.21+0.05 (+0.07%)Vol746.07K